Supplementary Figure S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Federico Rojo; Clive R. Taylor; Carlos H. Barrios; Laura Torrecillas; Manuel Ruíz-Borrego; Sandra Pérez‐Buira; José Bines; Ángel Guerrero‐Zotano; José Á. García-Sáenz; Roberto Torres; Juan de la Haba-Rodríguez; Francisco Ayala; Henry Gómez; Antonio Llombart‐Cussac; María Rodríguez de la Borbolla; José Manuel Baena-Cañada; Agustí Barnadas; Lourdes Calvo; Jesús Herránz; Raúl Rincón; Rosalía Caballero; Begoña Bermejo; Partha S. Ray; Miguel Martín

doi:10.1158/1078-0432.30029044

Key Points

FOXC1 expression predicts capecitabine efficacy in triple-negative breast cancer patients, impacting treatment decisions.
Patients assigned to capecitabine showed improved disease-free survival compared to those under observation.
This analysis is part of the GEICAM_CIBOMA trial exploring treatment options for breast cancer.
Findings highlight the importance of FOXC1 as a biomarker for therapeutic response in breast cancer treatments.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Survival analyses reveal disease-free survival outcomes for capecitabine vs observation in patients, suggesting potential predictive value of FOXC1 expression.

Abstract

Survival analyses showing the secondary endpoint of disease-free survival (DFS) for patients randomly assigned to capecitabine or observation in the GEICAM_CIBOMA translational study cohort

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rojo et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f67b https://doi.org/10.1158/1078-0432.30029044

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading